L3VLUP
ProSign in

TAK · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TAKLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TAK
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterTAKLLY
Q3 20204 holders, $423m33 holders, $14.1bn
Q4 20205 holders, $549m29 holders, $17.3bn
Q1 20214 holders, $699m24 holders, $23.0bn
Q2 20214 holders, $476m24 holders, $27.8bn
Q3 20214 holders, $410m31 holders, $29.9bn
Q4 20212 holders, $111m31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 20223 holders, $69m33 holders, $42.7bn
Q3 20223 holders, $68m31 holders, $43.4bn
Q4 20225 holders, $208m31 holders, $46.6bn
Q1 20235 holders, $349m33 holders, $44.3bn
Q2 20235 holders, $353m37 holders, $59.6bn
Q3 20234 holders, $311m44 holders, $67.6bn
Q4 20235 holders, $374m45 holders, $73.6bn
Q1 20243 holders, $228m41 holders, $95.3bn
Q2 20244 holders, $243m43 holders, $110bn
Q3 20243 holders, $236m45 holders, $107bn
Q4 20243 holders, $271m46 holders, $93.9bn
Q1 20253 holders, $256m42 holders, $98.4bn
Q2 20252 holders, $257m43 holders, $93.2bn
Q3 20252 holders, $253m39 holders, $86.7bn
Q4 20254 holders, $355m41 holders, $123bn
Q1 20263 holders, $467m39 holders, $106bn
Q2 20263 holders, $410m44 holders, $132bn
TAK

Takeda Pharmaceutical Co Ltd

Holders
2
Reported value
$257m
Buyers
2
Sellers
0

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TAK (1)

Renaissance Technologies LLC

Only LLY (42)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, and 17 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →